|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BCL9L |
Gene summary for BCL9L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BCL9L | Gene ID | 283149 |
| Gene name | BCL9 like | |
| Gene Alias | B9L | |
| Cytomap | 11q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q86UU0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 283149 | BCL9L | LZE4T | Human | Esophagus | ESCC | 2.72e-02 | 6.16e-02 | 0.0811 |
| 283149 | BCL9L | LZE20T | Human | Esophagus | ESCC | 2.29e-02 | 9.41e-02 | 0.0662 |
| 283149 | BCL9L | LZE22D1 | Human | Esophagus | HGIN | 8.29e-03 | 2.67e-01 | 0.0595 |
| 283149 | BCL9L | LZE22T | Human | Esophagus | ESCC | 2.37e-18 | 9.06e-01 | 0.068 |
| 283149 | BCL9L | LZE24T | Human | Esophagus | ESCC | 1.73e-09 | 1.73e-01 | 0.0596 |
| 283149 | BCL9L | P1T-E | Human | Esophagus | ESCC | 3.27e-03 | 3.23e-01 | 0.0875 |
| 283149 | BCL9L | P2T-E | Human | Esophagus | ESCC | 1.17e-07 | 1.49e-01 | 0.1177 |
| 283149 | BCL9L | P4T-E | Human | Esophagus | ESCC | 1.35e-09 | 1.04e-01 | 0.1323 |
| 283149 | BCL9L | P5T-E | Human | Esophagus | ESCC | 5.74e-07 | 9.68e-02 | 0.1327 |
| 283149 | BCL9L | P8T-E | Human | Esophagus | ESCC | 1.72e-08 | 2.95e-01 | 0.0889 |
| 283149 | BCL9L | P9T-E | Human | Esophagus | ESCC | 4.95e-10 | 1.56e-01 | 0.1131 |
| 283149 | BCL9L | P10T-E | Human | Esophagus | ESCC | 4.34e-14 | 1.76e-01 | 0.116 |
| 283149 | BCL9L | P11T-E | Human | Esophagus | ESCC | 2.84e-07 | 3.17e-01 | 0.1426 |
| 283149 | BCL9L | P12T-E | Human | Esophagus | ESCC | 1.62e-13 | 1.16e-01 | 0.1122 |
| 283149 | BCL9L | P15T-E | Human | Esophagus | ESCC | 2.02e-04 | 1.33e-01 | 0.1149 |
| 283149 | BCL9L | P16T-E | Human | Esophagus | ESCC | 4.49e-05 | 5.84e-02 | 0.1153 |
| 283149 | BCL9L | P17T-E | Human | Esophagus | ESCC | 5.35e-04 | 1.63e-01 | 0.1278 |
| 283149 | BCL9L | P21T-E | Human | Esophagus | ESCC | 1.78e-13 | 2.42e-01 | 0.1617 |
| 283149 | BCL9L | P23T-E | Human | Esophagus | ESCC | 2.05e-06 | 1.04e-01 | 0.108 |
| 283149 | BCL9L | P24T-E | Human | Esophagus | ESCC | 6.72e-06 | 9.36e-02 | 0.1287 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001605516 | Esophagus | HGIN | Wnt signaling pathway | 83/2587 | 444/18723 | 2.27e-03 | 2.33e-02 | 83 |
| GO:019873816 | Esophagus | HGIN | cell-cell signaling by wnt | 83/2587 | 446/18723 | 2.58e-03 | 2.55e-02 | 83 |
| GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
| GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
| GO:00715599 | Esophagus | ESCC | response to transforming growth factor beta | 157/8552 | 256/18723 | 2.95e-07 | 4.23e-06 | 157 |
| GO:006007016 | Esophagus | ESCC | canonical Wnt signaling pathway | 180/8552 | 303/18723 | 9.15e-07 | 1.17e-05 | 180 |
| GO:00715609 | Esophagus | ESCC | cellular response to transforming growth factor beta stimulus | 151/8552 | 250/18723 | 1.78e-06 | 2.10e-05 | 151 |
| GO:00107184 | Esophagus | ESCC | positive regulation of epithelial to mesenchymal transition | 40/8552 | 52/18723 | 4.25e-06 | 4.56e-05 | 40 |
| GO:002260420 | Esophagus | ESCC | regulation of cell morphogenesis | 180/8552 | 309/18723 | 5.19e-06 | 5.45e-05 | 180 |
| GO:00071799 | Esophagus | ESCC | transforming growth factor beta receptor signaling pathway | 121/8552 | 198/18723 | 8.26e-06 | 8.03e-05 | 121 |
| GO:00018378 | Esophagus | ESCC | epithelial to mesenchymal transition | 95/8552 | 157/18723 | 1.25e-04 | 8.56e-04 | 95 |
| GO:000717810 | Esophagus | ESCC | transmembrane receptor protein serine/threonine kinase signaling pathway | 195/8552 | 355/18723 | 2.58e-04 | 1.58e-03 | 195 |
| GO:00487628 | Esophagus | ESCC | mesenchymal cell differentiation | 133/8552 | 236/18723 | 5.94e-04 | 3.22e-03 | 133 |
| GO:00107174 | Esophagus | ESCC | regulation of epithelial to mesenchymal transition | 61/8552 | 99/18723 | 1.01e-03 | 5.09e-03 | 61 |
| GO:00170156 | Esophagus | ESCC | regulation of transforming growth factor beta receptor signaling pathway | 75/8552 | 128/18723 | 2.19e-03 | 9.71e-03 | 75 |
| GO:19038447 | Esophagus | ESCC | regulation of cellular response to transforming growth factor beta stimulus | 76/8552 | 131/18723 | 2.96e-03 | 1.24e-02 | 76 |
| GO:00604856 | Esophagus | ESCC | mesenchyme development | 156/8552 | 291/18723 | 3.76e-03 | 1.53e-02 | 156 |
| GO:002260422 | Liver | HCC | regulation of cell morphogenesis | 188/7958 | 309/18723 | 4.84e-11 | 1.82e-09 | 188 |
| GO:019873821 | Liver | HCC | cell-cell signaling by wnt | 247/7958 | 446/18723 | 2.11e-08 | 4.96e-07 | 247 |
| GO:001605521 | Liver | HCC | Wnt signaling pathway | 245/7958 | 444/18723 | 3.68e-08 | 8.09e-07 | 245 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BCL9L | SNV | Missense_Mutation | rs200863037 | c.296N>T | p.Ala99Val | p.A99V | Q86UU0 | protein_coding | tolerated(0.29) | benign(0) | TCGA-A2-A4S2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
| BCL9L | SNV | Missense_Mutation | novel | c.2680N>A | p.Pro894Thr | p.P894T | Q86UU0 | protein_coding | tolerated(0.09) | benign(0) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| BCL9L | SNV | Missense_Mutation | novel | c.197N>A | p.Pro66His | p.P66H | Q86UU0 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-AR-A2LJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| BCL9L | SNV | Missense_Mutation | c.3290C>G | p.Pro1097Arg | p.P1097R | Q86UU0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A0C0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| BCL9L | SNV | Missense_Mutation | c.524C>A | p.Ala175Asp | p.A175D | Q86UU0 | protein_coding | deleterious(0.03) | possibly_damaging(0.64) | TCGA-BH-A0DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| BCL9L | SNV | Missense_Mutation | c.325G>A | p.Gly109Ser | p.G109S | Q86UU0 | protein_coding | tolerated(0.14) | possibly_damaging(0.622) | TCGA-BH-A1FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| BCL9L | insertion | In_Frame_Ins | novel | c.3332_3343dupCCACCTCAGACG | p.Ala1111_Asp1114dup | p.A1111_D1114dup | Q86UU0 | protein_coding | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| BCL9L | insertion | In_Frame_Ins | novel | c.4160_4161insTTG | p.Leu1387_Asn1388insCys | p.L1387_N1388insC | Q86UU0 | protein_coding | TCGA-A8-A09N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| BCL9L | deletion | Frame_Shift_Del | novel | c.472delN | p.Asp158ThrfsTer24 | p.D158Tfs*24 | Q86UU0 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| BCL9L | SNV | Missense_Mutation | rs34337307 | c.1897N>A | p.Val633Met | p.V633M | Q86UU0 | protein_coding | deleterious(0.05) | possibly_damaging(0.511) | TCGA-DG-A2KL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |